Shares of Nektar Therapeutics (NKTR) surged over 88% on Tuesday morning after reporting positive data from a mid-stage study in atopic dermatitis.
NKTR is currently trading at $18.00, up $8.46 or 88.68%, on a huge volume of on the Nasdaq. The stock opened its trading at $20.00 after closing Monday at $9.54. The stock has traded between $6.45 and $22.80 in the past 52-week period.
REZOLVE-AD is a phase IIb clinical trial evaluating the company's drug candidate Rezpegaldesleukin for the treatment of patients with moderate-to-severe atopic dermatitis. The study tested three doses of Rezpegaldesleukin - a high dose of 24 µg/kg every two weeks, a middle dose of 18 µg/kg every two weeks, and a low dose of 24 µg/kg every four weeks (q4w), or placebo.
Rezpegaldesleukin is a pegylated recombinant human interleukin-2 (IL-2) therapeutic.
The REZOLVE-AD study met its primary endpoint of the mean improvement in Eczema Area and Severity Score (EASI) from baseline at week 16 for all three dose arms of Rezpegaldesleukin versus placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.